New Details From Trump’s Drug Pricing Effort Put Branded Drugs in the Crosshairs

Drugmakers will be expected to commit to aligning U.S. prices with the lowest price set in a group of peer nations for all brand products across all markets that do not currently have generic or biosimilar competition.

Scroll to Top